Dr. Rugo on Hormone Therapy for Patients With Breast Cancer

Hope S. Rugo, MD
Published: Monday, Nov 06, 2017



Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Oncologists are focusing on trying to find agents that make hormone therapy work better for patients with hormone receptor-positive breast cancer, which may help them further understand latency, explains Rugo.

Ongoing clinical trials looking at adjuvant or post-neoadjuvant treatment with CDK 4/6 inhibitors versus placebo or standard of care will hopefully help oncologists learn more about preventing late recurrences, says Rugo.


Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Oncologists are focusing on trying to find agents that make hormone therapy work better for patients with hormone receptor-positive breast cancer, which may help them further understand latency, explains Rugo.

Ongoing clinical trials looking at adjuvant or post-neoadjuvant treatment with CDK 4/6 inhibitors versus placebo or standard of care will hopefully help oncologists learn more about preventing late recurrences, says Rugo.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x